{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:49:56Z","timestamp":1794376196913,"version":"4.9.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jacc.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T14:00:25Z","timestamp":1559570425000},"page":"2872-2891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1073,"title":["Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"73","author":[{"given":"Frederick L.","family":"Ruberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.04.003_bib1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.04.003_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2019.04.003_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.04.003_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib5","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis over the years 2000-2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.04.003_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.04.003_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib8","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib11","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.04.003_bib12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid","volume":"50","author":"Kelly","year":"1997","journal-title":"Adv Protein Chem"},{"key":"10.1016\/j.jacc.2019.04.003_bib14","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.04.003_bib15","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.04.003_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2017.1295371","article-title":"Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis","volume":"24","author":"Arvanitis","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib17","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.04.003_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jacc.2019.04.003_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","article-title":"Outcomes after cardiac transplant for wild type transthyretin amyloidosis","volume":"102","author":"Rosenbaum","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jacc.2019.04.003_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib23","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib25","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.04.003_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib29","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jacc.2019.04.003_bib31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.04.003_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jacc.2019.04.003_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib41","first-page":"113","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2019.04.003_bib42","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2019.04.003_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.04.003_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2019.04.003_bib46","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.amjcard.2014.07.058","article-title":"Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction","volume":"114","author":"Helder","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib48","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib49","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib51","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jacc.2019.04.003_bib53","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","article-title":"Wild-type transthyretin-derived amyloidosis in various ligaments and tendons","volume":"42","author":"Sueyoshi","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jacc.2019.04.003_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","article-title":"Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?","volume":"24","author":"Rubin","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2012.04.013","article-title":"The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients","volume":"164","author":"Dungu","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.04.003_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2019.04.003_bib58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2019.04.003_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.04.003_bib61","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in TTR-related versus AL cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib62","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archinte.1988.00380030168027","article-title":"Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement","volume":"148","author":"Pellikka","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib63","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.04.003_bib64","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib65","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.04.003_bib67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jacc.2019.04.003_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2019.04.003_bib69","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2019.04.003_bib72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.04.003_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2019.04.003_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib76","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.02.032","volume":"51","author":"Epstein","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib77","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A\u00a0study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.04.003_bib78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2019.04.003_bib79","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib80","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/tri.13326","article-title":"Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study","volume":"31","author":"Vollmar","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.jacc.2019.04.003_bib81","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10741-017-9601-z","article-title":"Heart transplantation in cardiac amyloidosis","volume":"22","author":"Sousa","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2019.04.003_bib82","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2019.04.003_bib83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"10","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib85","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib89","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.04.003_bib90","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacc.2019.04.003_bib91","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Scott","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.04.003_bib92","first-page":"219","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2019.04.003_bib93","series-title":"Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value evidence report","author":"Lasser","year":"2018"},{"key":"10.1016\/j.jacc.2019.04.003_bib94","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.04.003_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.04.003_bib96","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2019.04.003_bib97","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.04.003_bib98","doi-asserted-by":"crossref","first-page":"25080","DOI":"10.1038\/srep25080","article-title":"Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses","volume":"6","author":"Galant","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2019.04.003_bib99","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex\u00a0vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.04.003_bib100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84 12 Suppl 3","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719347291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719347291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:22:38Z","timestamp":1760016158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719347291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":100,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0735109719347291"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735894563.793583141","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}